BCL9 and colorectal carcinoma: Compound 32 inhibited the β-catenin/BCL9 PPI, but not β-catenin/E-cadherin PPI, in colorectal SW480, HCT116, HT29 CRC cells and triple-negative breast cancer cells MDA-MB-231 and MDA-MB-436, all overexpressing the Wnt signaling with IC50 values in the low micromolar range.